These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 29786888)
1. Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade. Yu S; Wang C; Yu J; Wang J; Lu Y; Zhang Y; Zhang X; Hu Q; Sun W; He C; Chen X; Gu Z Adv Mater; 2018 Jul; 30(28):e1801527. PubMed ID: 29786888 [TBL] [Abstract][Full Text] [Related]
2. Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. Chen Q; Chen G; Chen J; Shen J; Zhang X; Wang J; Chan A; Gu Z Nano Lett; 2019 Aug; 19(8):4879-4889. PubMed ID: 31294571 [TBL] [Abstract][Full Text] [Related]
3. A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade. Ruan H; Hu Q; Wen D; Chen Q; Chen G; Lu Y; Wang J; Cheng H; Lu W; Gu Z Adv Mater; 2019 Apr; 31(17):e1806957. PubMed ID: 30856290 [TBL] [Abstract][Full Text] [Related]
4. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128 [TBL] [Abstract][Full Text] [Related]
5. Injectable cold atmospheric plasma-activated immunotherapeutic hydrogel for enhanced cancer treatment. Fang T; Cao X; Shen B; Chen Z; Chen G Biomaterials; 2023 Sep; 300():122189. PubMed ID: 37307777 [TBL] [Abstract][Full Text] [Related]
6. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. Ye Y; Wang J; Hu Q; Hochu GM; Xin H; Wang C; Gu Z ACS Nano; 2016 Sep; 10(9):8956-63. PubMed ID: 27599066 [TBL] [Abstract][Full Text] [Related]
7. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy. Zhou L; Zhang P; Wang H; Wang D; Li Y Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102 [TBL] [Abstract][Full Text] [Related]
8. Injectable Anti-inflammatory Nanofiber Hydrogel to Achieve Systemic Immunotherapy Post Local Administration. Chen M; Tan Y; Dong Z; Lu J; Han X; Jin Q; Zhu W; Shen J; Cheng L; Liu Z; Chen Q Nano Lett; 2020 Sep; 20(9):6763-6773. PubMed ID: 32787149 [TBL] [Abstract][Full Text] [Related]
9. Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy. Chen Q; Sun M; Li Y; Huang L; Zu C; Kuang X; Zhao J; Hao M; Ma T; Li C; Tu J; Sun C; Du Y Nanomedicine; 2023 Sep; 53():102693. PubMed ID: 37343780 [TBL] [Abstract][Full Text] [Related]
10. A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy. Chen Q; Zhou S; Ding Y; Chen D; Dahiru NS; Tang H; Xu H; Ji M; Wang X; Li Z; Chen Q; Li Y; Tu J; Sun C J Control Release; 2022 Jun; 346():212-225. PubMed ID: 35461965 [TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy. Li L; Yang Z; Chen X Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161 [TBL] [Abstract][Full Text] [Related]
12. Programming Injectable DNA Hydrogels Yields Tumor Microenvironment-Activatable and Immune-Instructive Depots for Augmented Chemo-Immunotherapy. Fan Y; Zhan M; Liang J; Yang X; Zhang B; Shi X; Hu Y Adv Sci (Weinh); 2023 Oct; 10(29):e2302119. PubMed ID: 37541435 [TBL] [Abstract][Full Text] [Related]
13. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. Wang F; Su H; Xu D; Monroe MK; Anderson CF; Zhang W; Oh R; Wang Z; Sun X; Wang H; Wan F; Cui H Biomaterials; 2021 Dec; 279():121182. PubMed ID: 34688987 [TBL] [Abstract][Full Text] [Related]
15. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064 [TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
17. Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment. Chen Z; Rong Y; Ding J; Cheng X; Chen X; He C Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839750 [TBL] [Abstract][Full Text] [Related]
18. Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy. Huang J; Xiao Z; An Y; Han S; Wu W; Wang Y; Guo Y; Shuai X Biomaterials; 2021 Feb; 269():120636. PubMed ID: 33453632 [TBL] [Abstract][Full Text] [Related]
19. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492 [TBL] [Abstract][Full Text] [Related]
20. Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. Cheng K; Ding Y; Zhao Y; Ye S; Zhao X; Zhang Y; Ji T; Wu H; Wang B; Anderson GJ; Ren L; Nie G Nano Lett; 2018 May; 18(5):3250-3258. PubMed ID: 29683683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]